Last reviewed · How we verify
18F-FCH
At a glance
| Generic name | 18F-FCH |
|---|---|
| Also known as | N,N-Dimethyl-N-Fluoromethylethanolamine |
| Sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors (PHASE2,PHASE3)
- Expanded Access:18F-Fluorocholine for the Detection of Parathyroid Adenomas
- Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma (PHASE3)
- Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma (PHASE2)
- D4 Choline Breast PET/CT
- Fluorocholine PET/CT Basket Trial (PHASE3)
- Multi-modality Prostate Cancer Image Guided Interventions (NA)
- FCH PET/MRI Parathyroid Localization (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 18F-FCH CI brief — competitive landscape report
- 18F-FCH updates RSS · CI watch RSS
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) portfolio CI